Latest News

Enhanced Outcomes with Relatlimab, Nivolumab, and Chemotherapy in Advanced Non-Small Cell Lung Cancer
Enhanced Outcomes with Relatlimab, Nivolumab, and Chemotherapy in Advanced Non-Small Cell Lung Cancer

September 14th 2024

Adding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone.

Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC
Zipalertinib Shows Promise in Heavily Pretreated EGFR Exon 20-Mutated NSCLC

September 14th 2024

Early Zidesamtinib Data Appear Promising for ROS1+ NSCLC
Early Zidesamtinib Data Appear Promising for ROS1+ NSCLC

September 14th 2024

Low-Dose Pembrolizumab Shows Promise vs Standard Dose in Stage IV NSCLC
Low-Dose Pembrolizumab Shows Promise vs Standard Dose in Stage IV NSCLC

September 14th 2024

Upfront Belrestotug and Dostarlimab Betters Responses in PD-L1–High NSCLC
Upfront Belrestotug and Dostarlimab Betters Responses in PD-L1–High NSCLC

September 14th 2024

Video Series
Video Interviews
Podcasts

More News